• Branched Endosomal Disruptor Lipids Advance mRNA Delivery Ef

  2026-06-30

  The reference study introduces branched endosomal disruptor (BEND) lipids, a novel class of ionizable lipids, which significantly improve mRNA and CRISPR-Cas9 ribonucleoprotein (RNP) delivery by enhancing endosomal escape. These findings have direct implications for hepatic gene editing and T cell engineering, addressing longstanding challenges in efficient, safe, and targeted mRNA transfection in mammalian cells.

• Tin Mesoporphyrin IX: Precision Heme Oxygenase Inhibition in

  2026-06-30

  Tin Mesoporphyrin IX (chloride) enables nanomolar-precision inhibition of heme oxygenase, streamlining experimental workflows in oxidative stress, metabolic disease, and viral replication research. This guide delivers actionable protocol insights, troubleshooting methods, and comparative perspectives for advanced scientific investigations.

• Canagliflozin: Optimizing SGLT2 Inhibitor Workflows in Renal

  2026-06-29

  Canagliflozin delivers more than glycemic control—enabling targeted mitochondrial remodeling and kidney protection in diabetes models. This guide translates novel mechanistic insights and validated protocols into practical, high-reproducibility workflows for metabolic and renal research teams.

• TRIM66 Controls Monogenic Olfactory Receptor Expression via

  2026-06-29

  This study uncovers TRIM66 as a critical epigenetic repressor responsible for enforcing the singular expression of olfactory receptor genes in mouse sensory neurons. By dissecting the molecular mechanisms that restrict each neuron to one receptor gene, the work clarifies a longstanding question in sensory biology and supports a framework for future research on neuronal identity and sensory coding.

• Niclosamide in Cancer Research: Applied Workflows & Optimiza

  2026-06-28

  Niclosamide, a potent STAT3 pathway inhibitor, delivers precise control in cancer research models—enabling robust cell cycle arrest and apoptosis assays. This article dissects optimized protocols, troubleshooting strategies, and insights from recent quantitative drug response studies, empowering researchers to maximize experimental clarity.

• SW033291: 15-PGDH Inhibitor Workflows for Regeneration Resea

  2026-06-27

  SW033291 stands out as a high-potency 15-PGDH inhibitor, uniquely enabling precise prostaglandin E2 elevation for muscle and hematopoietic stem cell regeneration models. This guide translates recent breakthrough findings into actionable protocols and troubleshooting strategies for robust, reproducible results in tissue regeneration research.

• JPA Enhances Metabolic Feature Detection in LC-MS Metabolomi

  2026-06-26

  The reference study introduces JPA, an R package for joint metabolic feature extraction, which significantly broadens chemical coverage in LC-MS-based metabolomics and exposomics. By integrating conventional and MS2-guided strategies, JPA improves sensitivity and accuracy, rescuing key metabolic features missed by standard approaches and enabling deeper biomarker and exposome research.

• Ionomycin Free Acid and Calcium Ionophores: Advancing FAK-FA

  2026-06-26

  Explore how Ionomycin free acid, a selective calcium ionophore, enables deeper mechanistic studies of FAK regulation and lncRNA FAISL in triple negative breast cancer (TNBC). This article offers unique technical guidance and workflow context for researchers seeking to optimize calcium-mediated signaling assays.

• CLK2 Inhibition to Overcome Platinum Resistance in Ovarian C

  2026-06-25

  This study identifies Cdc2-like kinase 2 (CLK2) as a key driver of platinum resistance in ovarian cancer by enhancing DNA damage repair through BRCA1 phosphorylation. Targeting CLK2 offers a mechanistically supported approach for sensitizing resistant tumors and informs new therapeutic strategies in alternative splicing modulation and cancer treatment.

• Type III Collagen’s Tumor-Restrictive Role in Breast Cancer

  2026-06-25

  This study uncovers the tumor-suppressive function of type III collagen in the breast cancer microenvironment, demonstrating its association with improved patient outcomes and reduced tumor progression. By integrating in vitro, in vivo, and bioinformatic analyses, the research highlights type III collagen as a potential prognostic marker and therapeutic target for limiting breast cancer recurrence.

• 20 Years of Toremifene Data: Endocrine Therapy in Breast Can

  2026-06-24

  The referenced review consolidates two decades of clinical and translational data on toremifene, a selective estrogen receptor modulator, as a treatment for estrogen receptor-positive breast cancer. It highlights the evolution of personalized endocrine therapy, the clinical equivalence of toremifene and tamoxifen, and the importance of biomarker-driven approaches for patient stratification.

• GS-441524 Prodrug: Pharmacokinetics and Assay Strategy Unvei

  2026-06-23

  Explore the pharmacokinetics and conversion pathways of GS-441524, a leading anti-SARS-CoV-2 nucleoside analog. This article delivers new insights into prodrug design, LC–MS/MS assay optimization, and practical decision-making for antiviral research.

• Bestatin Hydrochloride: Dissecting Aminopeptidase Inhibition

  2026-06-23

  Explore the dual role of Bestatin hydrochloride (Ubenimex) in neuromodulation and tumor biology, with a focus on its mechanistic insights and assay design. This article offers a unique analysis bridging neuropeptide regulation and cancer research, grounded in foundational evidence.

• Selective IRAP Inhibitors: Advances from Bestatin Derivative

  2026-06-22

  This study introduces a new class of α-hydroxy-β-amino acid derivatives, inspired by Bestatin, as highly selective nanomolar inhibitors of insulin-regulated aminopeptidase (IRAP). The research demonstrates a structure-guided approach that achieves remarkable selectivity and potency, offering valuable chemical tools for probing M1 aminopeptidase function and informing future drug development.

• BET Inhibition in HPV-16+ Head and Neck Cancer: Mechanistic

  2026-06-22

  This study dissects the transcriptional effects of BET protein inhibition in HPV-16-associated head and neck squamous cell carcinoma (HNSCC), revealing heterogeneous responses and direct modulation of viral and host oncogenes. The findings highlight both mechanistic nuance and workflow strategies for epigenetics and cancer biology research.

8009 records 7/534 page Previous Next First page 上5页 678910 下5页 Last page